SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin discussion remains highly fragmented, with traders divided between bullish sentiment citing long-term technical formations like inverted head-and-shoulders and accumulation patterns, and bearish criticism focused on the asset's persistent underperformance and historical weakness against other major cryptocurrencies.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending following a record fiscal second-quarter earnings report that featured a revenue beat and surprise non-GAAP profitability, though investor sentiment remains divided due to cautious third-quarter revenue guidance and recent price volatility. While some traders view the company as a strong defense and intelligence play with a significant backlog, others are expressing frustration over the stock's recent performance and are focused on the impact of prior share dilution.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as investors monitor the anticipation of a U.S. Supreme Court decision on the litigation with Hikma and await developments regarding the company's patent and product lifecycle strategy. The community remains divided between those expressing frustration over long-term price stagnation and those maintaining a bullish outlook based on potential M&A activity and the clinical value of the icosapent ethyl franchise.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The community discussion remains focused on potential short-term catalysts, such as international label expansion and oncology conference data, while expressing continued frustration with stock price suppression by institutional shorts. Traders are debating the company's valuation, weighing its pipeline potential against regulatory hurdles and dilution concerns.

Cheesecake Factory, Inc. engages in the operation of restaurant chains. It operates through the following segments: The Cheesecake Factory Restaurants, North Italia, Other FRC, and Other. The Cheesecake Factory Restaurants segment offers appetizers, pizza, seafood, steaks, chicken, burgers, small plates, pastas, salads, sandwiches and omelettes, and a selection of gluten-free items. The North Italia segment specializes in Italian cuisine. The Other FRC segment includes brands acquired from Fox Restaurant Concepts. The Other segment consists of the Flower Child brand, along with other businesses. The company was founded by David M. Overton, Oscar Overton, and Evelyn Overton in 1972 and is headquartered in Calabasas Hills, CA.

Cheesecake Factory Inc. (The)

Cheesecake Factory Inc.

Cheesecake Factory is trending amid intense debate between traders over its parabolic, multi-month rally and extreme RSI levels, with many retail investors debating whether to take profits or short the stock against perceived overvaluation. While some highlight recent blowout earnings and strong performance of newer growth concepts, others cite significant insider selling and a lack of volume as signals that the stock is a bubble ripe for a sharp reversal.

Honeywell Aerospace, Inc. engages in the provision of aerospace and defense critical systems and technologies. It operates through the following segments: Electronic Solutions, Engines & Power Systems, and Control Systems. The Electronic Solutions segment supplies aerospace electronic systems and technologies such as avionics and navigation sensors and electromagnetic defensive solutions. The Engine & Power Systems segment manufactures propulsion systems, APUs, and electric power solutions. The Control Systems segment handles the supply of thermal and motion control systems that enable flight, life support, and safety for the aircraft. The company was founded in 1914 and is headquartered in Phoenix, AZ.

Honeywell Aerospace Inc

Honeywell Aerospace

Honeywell Aerospace is attracting attention following a significant recovery from its post-spinoff selloff, bolstered by positive analyst commentary regarding the company's valuation and long-term potential in the defense and aerospace sectors. Traders are closely monitoring the stock's ability to clear technical resistance levels and manage supply chain bottlenecks amid strong demand.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is receiving attention due to its recent v5.0 mainnet upgrade, which introduced native post-quantum secure accounts, fueling community speculation about the project's potential in a future quantum-resistant landscape. Sentiment remains deeply divided, with bulls highlighting the technical advancements and institutional adoption, while skeptics point to historical price declines, token dilution, and long-standing debates over accumulation phases versus long-term failure.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following a record-breaking second-quarter earnings report, where the company posted significant revenue growth and a record contract backlog. Investors are also closely monitoring the company's multi-launch agreement extension with Lockheed Martin through 2031 and its ongoing efforts to ramp up production amidst high industry demand.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is trending after being selected to join the S&P 500 index during the upcoming quarterly rebalance, prompting significant buying interest from traders and index-tracking funds. While many in the community view this inclusion as a long-term bullish catalyst and a validation of the company's role in the AI data center energy sector, some traders remain skeptical, debating whether the move is already priced in or if it will face a "sell the news" correction similar to past index additions.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

The conversation surrounding UVIX is dominated by speculation on an imminent volatility spike, with traders debating whether upcoming geopolitical tensions and macroeconomic concerns will trigger a market correction after Labor Day. While some participants are aggressively accumulating the asset in anticipation of a significant surge, others are expressing frustration over the ETF's performance, citing structural decay and a disconnect from recent market price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New...

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts...

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason OByrne is leaving the Company to pursue another opportunity and will remain with Vir...

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the...

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. We are pleased to welcome Tim to Vir Biotechnologys Board of Directors at a pivotal moment for the company, said Marianne...

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now...

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Equity

Neutral Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.74	--	--	N/A
Q2 '26	$0.33	$0.47	41.31%	BEAT
Q1 '26	-$0.10	-$0.85	-790.05%	MISSED
Q4 '25	-$0.49	-$0.31	36.88%	BEAT
Q3 '25	-$0.84	-$1.17	-38.64%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

VIR Earnings

Upcoming Earnings: Q3 '26

Historical Earnings